New Virus-Like Particle Vaccine Offers Protection Against Chikungunya
A significant breakthrough in infectious disease prevention has arrived with the introduction of a recombinant virus-like particle (VLP) vaccine designed to combat the chikungunya virus. This single-dose vaccine represents a critical tool for individuals aged 12 years and older who are traveling to or residing in regions where the virus is prevalent.
What is VIMKUNYA and How Does it Work?
VIMKUNYA is a recombinant vaccine that utilizes VLP technology. Unlike traditional vaccines that may employ weakened or inactivated viruses, VIMKUNYA contains proteins that assemble into particles mimicking the structure of the chikungunya virus.
Crucially, these particles contain no actual viral genetic material. Because they lack this genetic blueprint, the vaccine cannot infect cells or replicate, meaning it cannot cause the disease it is designed to prevent. This approach allows the immune system to recognize the virus’s “shape” and build a defense without the risks associated with live viral components.
Current Recommendations and Eligibility
According to draft recommendations from the Advisory Committee on Immunization Practices (ACIP), the VLP chikungunya vaccine is recommended for persons aged 12 years and older who are traveling to a country or territory experiencing a chikungunya outbreak.
the vaccine may be considered for individuals aged 12 years and older who are traveling to or taking up residence in areas that do not currently have an active outbreak but maintain elevated levels of the virus.
Clinical Evidence and Safety
The development of the VLP-based vaccine, including candidates like PXVX0317, has undergone rigorous testing through phase 3 randomized, double-blind, placebo-controlled trials in adolescents and adults within the USA.
Research has as well explored how the vaccine performs in different populations. A phase 2 randomized controlled trial examined adults aged 18-65 to determine if previous exposure to other alphavirus vaccines—such as an investigational Venezuelan equine encephalitis virus vaccine—would impair the immune response to the chikungunya VLP vaccine. The study focused on seroconversion 21 days after a single 40 μg dose, measuring the increase in neutralizing antibodies.
- Target Audience: Recommended for individuals aged 12+ traveling to or living in areas with chikungunya outbreaks or elevated risk.
- Technology: Uses Virus-Like Particles (VLPs) that mimic the virus but contain no genetic material and cannot replicate.
- Dosage: Administered as a single-dose vaccine.
- Safety: Cannot cause chikungunya disease because it lacks the genetic material required to infect cells.
Frequently Asked Questions
Can this vaccine cause chikungunya?
No. Because the VLP vaccine contains no viral genetic material, it cannot replicate or infect cells, making it impossible for the vaccine to cause the disease.
Who should receive the vaccine?
It is recommended for people 12 years of age and older traveling to regions with active chikungunya outbreaks, and may be considered for those moving to or visiting areas with elevated virus prevalence.
How is the vaccine administered?
Clinical data indicates the vaccine is administered via intramuscular injection.
As global travel increases and virus prevalence shifts, the availability of a single-dose VLP vaccine provides a streamlined and safe method for preventing chikungunya, reducing the burden of disease for travelers and expatriates alike.